Trials / Completed
CompletedNCT03625882
Survey Study for Velaglucerase Alfa (VPRIV) in Japan
VPRIV Drug Use-Result Survey (Japan)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 63 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.
Conditions
Timeline
- Start date
- 2014-09-02
- Primary completion
- 2024-05-14
- Completion
- 2024-05-14
- First posted
- 2018-08-10
- Last updated
- 2026-03-04
- Results posted
- 2025-01-10
Locations
35 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03625882. Inclusion in this directory is not an endorsement.